From - A Hematology Oncology Wiki
Jump to navigation Jump to search

1 regimens on this page
1 variants on this page

Advanced or metastatic disease, all lines of therapy

Selpercatinib monotherapy


Study Years of enrollment Evidence
Subbiah et al. 2022 (LIBRETTO-001)
12/4/2017-8/4/2021 Phase 1/2 (RT)

Note: this is the phase 2 recommended dosing.

Targeted therapy

Continued indefinitely


  1. LIBRETTO-001: Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K, Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-1273. Epub 2022 Sep 12. link to original article PubMed NCT03157128